Tumor cells engineered to express therapeutic agents have shown promise to treat cancer. However, their potential to target cell surface receptors specific to the tumor site and their posttreatment fate have not been explored. We created therapeutic tumor cells expressing ligands specific to primary and recurrent tumor sites (receptor self-targeted tumor cells) and extensively characterized two different approaches using (i) therapy-resistant cancer cells, engineered with secretable death receptor-targeting ligands for "off-the-shelf" therapy in primary tumor settings, and (ii) therapy-sensitive cancer cells, which were CRISPR-engineered to knock out therapy-specific cell surface receptors before engineering with receptor self-targeted ligands and reapplied in autologous models of recurrent or metastatic disease. We show that both approaches allow high expression of targeted ligands that induce tumor cell killing and translate into marked survival benefits in mouse models of multiple cancer types. Safe elimination of therapeutic cancer cells after treatment was achieved by co-engineering with a prodrugconverting suicide system, which also allowed for real-time in vivo positron emission tomography imaging of therapeutic tumor cell fate. This study demonstrates self-tumor tropism of engineered cancer cells and their therapeutic potential when engineered with receptor self-targeted molecules, and it establishes a roadmap toward a safe clinical translation for different cancer types in primary, recurrent, and metastatic settings.
INTRODUCTION
Combined advances in the fields of biomedical research, drug de velopment, medical imaging, and surgical techniques have translated into considerably improved outcomes of cancer patients over the last decades (1) . The resulting impact of therapy improvement on even highly malignant tumors, which have previously been consid ered "untreatable," including lung cancer and melanoma, has recently led to excitement in the medical and scientific oncology fields. Never theless, numerous local and systemic cancer types, as well as many forms of metastatic disease, remain ultimately fatal, and treatment regimes in endstage disease, especially in the recurrent setting, of ten lack evidencebased guidelines.
One of the major treatment hurdles of advancedstage cancer is localized and distant tumor cell metastasis, resulting from vascular infiltration or penetration of anatomic boundaries (2, 3) . A growing body of evidence suggests that tumor progression at this stage may be enhanced by circulating cancer cells' ability of "selfseeding," a process involving cell dissemination into the vascular system away from a primary or metastatic tumor, followed by the cells rehoming to the site of origin (4) . In recent years, several studies have tried to repurpose the tumor cells' selfhoming properties for selftargeted delivery of anticancer agents to primary tumor sites. The most prom ising approaches included using tumor cells as a vehicle for delivery of oncolytic viruses (5, 6) , using engineered tumor cells expressing suicide genes to transfer death signals to neighboring tumor cells (bystander effect) (7, 8) , and targeting the tumor microenvironment by engineering cancer cells to express therapeutic agents that influ ence tumors' neovascular endothelium (9) . Naturally, engineering tumor cells for selftargeted anticancer treatment is a doubleedged sword: Premature cell death due to selftoxicity of introduced trans genes may limit their antitumor efficacy, whereas longterm survival of therapeutic cells may potentially cause secondary tumor forma tion, even if they are initially efficacious in treating the targeted self tumor site. Consequently, to our best knowledge, none of the previous studies that involved rehoming of tumor cells followed a truly receptorspecific selftargeted approach, likely to avoid auto crine toxicity.
Much of the abovementioned progress recently seen in cancer therapies is ultimately a result of advances in the field of receptor targeted therapies (10, 11) , where disease or cancerspecific (over) expression of cell surface receptors is targeted to modulate down stream pathways involved in functions such as proliferation/survival, cell cycle regulation, metabolism, angiogenesis, inflammation, or immune response. To improve therapy success, it has therefore be come increasingly common to categorize patients according to their diseasespecific (receptor) gene expression profiles. In cancer ther apies, targeting proliferative or triggering proapoptotic receptor mediated pathways has proven especially attractive (12) (13) (14) . In previous investigations, the feasibility of combining receptortargeted treatments with cellbased therapies and associated benefits have been shown in distinct tumor settings (15) (16) (17) . Here, we screened a panel of different cancer types for their responses to surface recep tor ligands/antagonists that target cell proliferation and death path ways and identified the secretory variant of TNF (tumor necrosis factor)-related apoptosisinducing ligand [STRAIL (hereinafter ST)] as a promising antitumor agent because of its ability to strongly in duce apoptosis in a wide variety of different cancer types, without causing considerable toxicity in normal cells (18) (19) (20) .
Building on the above findings, we hypothesized that, by apply ing recent advances in bioengineering, we could simultaneously prevent receptormediated autocrine toxicity and combine the self homing properties of cancer cells with the benefits of receptor targeted treatment and inducible suicide system-related bystander effect/clearance. To test the clinical feasibility of this approach in firstline treatment of primary tumors, as well as in the therapy of recurrent and metastatic disease, we explored two different ap proaches: (i) an "offtheshelf " allogeneic option for treatment of primary tumors with preengineered, therapyresistant tumor cells, which, in a clinical setting, would be selected to match the patients' human leukocyte antigen (HLA) phenotype (Fig. 1A) , and (ii) an "autologous" approach for treatment in the recurrent setting, which uses clustered regularly interspaced short palindromic repeats (CRISPR) technology to switch the treatment response phenotype of the therapeutic cells from therapysensitive to therapy resistant before engineering with therapeutic molecules (Fig. 1B) . We demonstrate that these approaches allow high expression of proapoptotic molecules without inflicting autocrine toxicity, which, in combination with selfhoming and suicide system-mediated by stander effect/clearance, translates into marked survival benefits in mouse models of multiple cancer types.
RESULTS

Death receptor 4/5-targeted therapy demonstrates potent anticancer efficacy
To investigate the therapeutic efficacy of receptortargeted molecules, we tested a panel of different cancer cell lines for their susceptibility to treatment with cell surface receptor ligands/antagonists targeting CD36 (thrombospondin1), epidermal growth factor receptor (EGFR) (EGFRblocking nanobody), heterodimeric interleukin20 receptor (IL20R) composed of subunits  and  (IL24), and death receptors (DRs) (TRAIL) (Fig. 1C) . A nodular (n) and an invasive (i) GBM cell line (Gli36EGFR and GBM8, respectively) were screened and found to be DR ligand (DR L )-sensitive (s) (herein referred to as sGBMn and sGBMi). The following nonGBM cancer lines were also identified as DR L sensitive: PC3 (sPCm), Jurkat (sTCL), HCT116 (sCC), and MDA231BrM2a (sBCm). In comparison to the other tested ligands, the DR L TRAIL was the most effective agent, with potential to eliminate treated cell lines at 72 hours after treatment (Fig. 1C) . In addition to the above DR L sensitive (s) cell lines, three DR L resistant (r) GBM cell lines were identified (GBM23, GBM64, and GBM46, herein referred to as rGBMi1, rGBMi2, and rGBMi3) (Fig. 1D) . On the basis of these findings, DR4 and DR5 were chosen as the most suitable candidates to further investigate the therapeutic potential of receptor selftargeted therapies.
DR L -resistant tumor cells can be engineered to express ST and have antitumor effects against DR L -sensitive cells
To test whether DR L resistant glioblastoma cells (rGBM) can serve as a vehicle for DR L delivery toward DR L sensitive tumors (sGBM) ( Fig. 2A) , we first analyzed DR expression of different rGBMs and sGBMi. Reverse transcription polymerase chain reaction (RTPCR) analysis demonstrated that sGBMi expresses DR4/5 ( fig. S1A ), which are necessary to activate TRAILinduced apoptosis. Lack of DR expression was seen only in one of the three DR L resistant lines ( fig. S1A ), indicating that cells with preserved DR expression can nonetheless exhibit TRAIL resistance, likely due to activation of antiapoptosis mechanisms. Next, we tested the feasibility of expression and secretion of DR L from invasive rGBMs (rGBMi) by engineer ing rGBMi1 and rGBMi2 with a secretable and potent variant of DR L (ST) or green fluorescent protein (GFP) (control). Cocul ture of rGBMi1ST and rGBMi2ST with sGBMi engineered with lentivirus (LV) expressing firefly luciferase (Fluc)-mCherry (sGBMi FmC) showed robust killing of sGBMiFmC cells over time, medi ated by caspaseinduced apoptosis (Fig. 2, B to D) . Furthermore, we transduced rGBMi1 and rGBMi2 with LV encoding a fusion variant of ST with the optical reporter Renilla luciferase [Rluc(o) (Rl)] (21) . Both rGBMi1RlST and rGBMi2RlST demonstrated continued secretion of ST into culture medium without autocrine toxicity of the therapeutic cells, as demonstrated by a timedependent in crease of bioluminescent imaging (BLI) signal intensity ( fig. S1B ). Coculture assays of rGBMi1RlST or rGBMi2RlST with sGBMi FmC further showed robust killing of sGBMi FmC cells over time ( fig. S1C ). Together, these data show that engineered rGBMs can continuously secrete ST without inflicting autocrine toxicity and have the potential to serve as a delivery vehicle of ST toward DR L sensitive tumor cells. Because of the superior therapeutic efficacy observed for rGBMi2ST compared to rGBMi1 ST, we selected rGBMi2ST for further study.
Prodrug-converting suicide system allows selective elimination of therapeutic rGBMs, and the bystander effect increases therapeutic efficacy of rGBM-ST To ensure safety, a measure to efficiently eliminate therapeutic rGBMs had to be incorporated into our approach. Thus, we next engineered rGBMi2 to either express a prodrugconverting enzyme (HSVTK) or coexpress ST, HSVTK, and diagnostic GFl (rGBMi2 TK and rGBMi2STTKGFl, respectively) and tested the efficacy of HSVTK/GCV-induced clearance of therapeutic rGBM in vitro. GCV treatment resulted in the dose and timedependent elimina tion of rGBMi2TK cells in comparison to controls (Fig. 2E) . In vivo noninvasive monitoring of intracranial rGBMi2TKGFl tumor growth in mice demonstrated that GCV treatment eliminated ther apeutic rGBMi2TKGFl as compared to salinetreated control (Fig. 2F) . In vivo GCVinduced cell clearance was further demon strated in a clinically relevant 18FFHBG PET imaging model using rGBMi2 coengineered with ST and TK (rGBMi2STTK) (Fig. 2G) . After 10 days of daily GCV treatment, the tumorspecific PET sig nal was no longer visible intracranially, with only unspecific ab dominal signal due to tracer clearance (22) remaining. Together, these results indicate that therapeutically engineered rGBMs can be selectively eliminated using HSVTK/GCV in vitro and in vivo and additionally demonstrate that therapeutic cell fate can be clinically monitored using PET imaging.
To examine the bystander effect of HSVTK/GCV, we tested the therapeutic efficiency of rGBMi2STTK or rGBMi2GFP via co culture with the DR L sensitive invasive GBM cell line sGBMiFmC. A significant reduction in sGBMiFmC viability was seen when co cultured with rGBMi2STTK within 24 hours (P < 0.05, with and without GCV), and at 96 hours, sGBMiFmC cells were completely eliminated when cocultures were treated with GCV and nearly com pletely eliminated under non-GCVtreated conditions (Fig. 2H) . Because they are co-engineered with a prodrug-activatable suicide system [herpes simplex virus thymidine kinase (HSV-TK)], therapeutic cancer cells can be eliminated after therapy using ganciclovir (GCV). (B) Autologous approach: Cancer cells harvested from patients during initial surgery and identified as sensitive to receptor-targeted therapies can be CRISPR-engineered to knock out the target receptors. Receptor knockout (KO) results in therapy resistance and allows engineering with receptor ligands and delivery toward autologous self-tumor sites in the setting of recurrence. (C) A panel of primary and metastatic cancer cell lines was treated with conditioned medium containing secretable variants of different receptor-targeted molecules, and viability was assessed 72 hours after treatment (n = 3 technical replicates). TSP, thrombospondin-1; Nb, nanobody. (D) Cancer cell lines were tested with varying concentrations of TRAIL to quantify TRAIL sensitivity (n = 3 technical replicates). TRAIL-sensitive (s) or -resistant (r), nodular (n) and invasive (i) glioblastoma (GBM), colon cancer (CC), T cell leukemia (TCL), metastatic breast cancer (BCm), and metastatic prostate cancer cells (PCm) were tested. All in vitro experiments were repeated at least twice. Means ± SD are shown. P values by unpaired t test. **P < 0.01, ***P < 0.001. and the respective Kaplan-Meier survival curves (right); n = 3 for phosphate-buffered saline (PBS), n = 5 for rGBMi2-GFP, and n = 6 for rGBMi2-ST-TK + GCV. All in vitro experiments were repeated at least twice. Means ± SD are shown for in vitro experiments and means ± SEM are shown for in vivo experiments. P values by unpaired t test (B and C) or Mantel-Cox (log-rank) test (J), *P < 0.05, ***P < 0.001.
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These results demonstrate that the introduction of HSVTK may not only serve to eliminate therapeutic cells but also further increase the therapeutic efficacy of STmediated apoptosis via additional bystander effect. However, likely because of the highly TRAILsensitive phe notype of sGBMiFmC, the observed difference between GCVtreated and non-GCVtreated conditions was not statistically significant (P > 0.05 at the 96hour time point).
Therapeutic rGBMs show efficacy against DR L sGBMs
To investigate the in vivo growth pattern of therapeutic rGBMs and their potential for targeting of allogeneic DR L sGBMs, mice bearing sGBMiFmC tumors were implanted with rGBMi2GFP at a dis tance of 1.5 mm from the sGBMiFmC tumor site. Fluorescence imaging of mouse brain sections showed extensive tracking of in vading sGBMiFmC cells by rGBMi2GFP, suggesting rGBMi2 GFP migration toward preimplanted sGBMiFmC in vivo (Fig. 2I) . Next, mice with established sGBMiFmC tumors were injected in tratumorally with either rGBMi2GFP (control) or therapeutic rGBMi2STTK cells. BLI revealed a marked reduction of sGBMi FmC tumor sizes in the rGBMi2STTK group, indicating a robust induction of cell death in sGBMiFmC cells (Fig. 2J ). After GCV treatment, the sGBMiFmC tumors regressed further, and the ther apeutic response translated into significant survival benefits for the mice (P < 0.05; Fig. 2J ). Together, these data indicate that therapeu tically armed DR L rGBM cells can efficiently deliver cell surface receptorspecific antitumor ligands toward established sGBM and mediate efficacy in vivo. Fig. 3D) , and genomic DNA sequencing identified indel mutations at SgRNAtargeted exonic gene segments of DR4, DR5, and DR4/5 doubleKO clones (Fig. 3E) . Together, these results demonstrate successful CRISPR engineering of DR L sGBM cells to knock out DR4, DR5, or both DR4 and DR5.
Cas9-mediated DR-KO in tumor cells confers resistance to DR-targeted therapy
Next, we tested whether DRKO correlates with a DR L resistant phenotype in vitro. Cell viability assay of DR4/5 intact sGBMn cells (GBMncontrol and GBMnCas9), as well as their DR4, DR5, and DR4/5 DRKO clones, identified DR5 as the more dominant recep tor in TRAILinduced apoptosis (Fig. 3F) . However, complete resis tance to DR L mediated apoptosis was only observed in the third doubleKO clone, GBMnDR4/53 ( Fig. 3F ). Cleaved caspase 8 and cleaved PARP analysis of STtreated sGBMn cells further confirmed reduced activation of TRAILmediated apoptosis in sGBMnDR singleKO clones (sGBMDR42 and sGBMDR51) compared to DRintact sGBMn cells and the fully resistant phenotype in the rGBMnDR4/5 doubleKO clone rGBMnDR4/53 (herein referred to as rGBMn DR4/5 ; Fig. 3G ). After verifying our DRKO strategy, we next aimed to extend the panel of DR4/5 doubleKO cell lines with the other cancer cell lines previously identified as TRAILsensitive (Fig. 1D ). Using the same approach, we achieved DR4/5 double KO of ST sPCm, sCC, and sBCm cell lines. In addition, DR4/5 double KO of sTCL and the invasive GBM cell line sGBMi was established by engineering with DR4/5 KO constructs as described above, followed by in vitro selec tion with ST exposure. Western blotting was used to confirm estab lishment of doubleKO lines (Fig. 3H) . Sequencing of genomic DNA from wildtype and DR4/5 doubleKO sBCm clone DR4/52 (herein referred to as rBCm DR4/5 ) further confirmed indel mutations of targeted exonic gene sequences ( fig. S2C ). In conclusion, our DR KO strategy can be applied to a variety of cancer types.
DR-KO tumor cells co-engineered with DR L and a suicide system exhibit self-targeting efficacy in autologous recurrent tumor models in vitro
To mimic the clinical scenario of using autologous cells, established after primary tumor surgery, for selftargeted ligand delivery (out lined in Fig. 1B) , we next aimed to establish mouse models of recurrent tumors as a platform to test the selftargeting efficacy of autologous CRISPRengineered therapeutic cells. Furthermore, with this approach, we wanted to gain insight into whether adjuvant therapy, as com monly initiated after firsttime tumor surgery, alters the TRAIL sensitivity phenotype of tumors (Fig. 4A ). sGBMn and sGBMi (Fig. 1C) were transduced with LV to express FmC ( fig. S3A ) and implanted intracranially into severe combined immunodeficient (SCID) mice. Tumorbearing mice were treated with temozolomide (TMZ), and therapy response was observed, as indicated by a reduction of the tumor cells' BLI signal (Fig. 4B) . After tumor recurrence, mice were sacrificed, tumor cells were harvested using fluorescence micros copy as guidance, and recurrent GBM cells (sGBMnRec and sGBMiRec) were established in culture. Cell viability assays of these recurrent GBM lines revealed increased resistance to TMZ, whereas sensitivity to DRtargeting ST was unchanged or increased compared to the primary GBM cells (Fig. 4C ). These findings suggest that adjuvant in vivo treatment with TMZ induces a TMZresistant phenotype in recurrent tumors but does not negatively influence response to DRtargeted therapy.
In light of the highly TRAILresistant phenotype observed af ter DRKO, we next wanted to test whether the established DR4/5 doubleKO lines could serve as a cellular vehicle for continuous de livery of ST toward autologous selfcells and ultimately be eliminated. To test this hypothesis, we transduced rGBMn DR4/5 and rGBMi STTK with their respec tive recurrent lines further revealed high potential for selftargeting, resulting in marked reduction of the targeted recurrent GBM cells in a dosedependent manner as compared to coculture with GFP controls (Fig. 4D) .
Treatment of both nodular and invasive rGBMn DR4/5 STTK and rGBMi DR4/5 STTK with GCV resulted in dosedependent cell elim ination as opposed to nonTK control lines (Fig. 4E) . To further test whether HSVTK bystander effect might also provide efficacy against TRAILresistant autologous selfcells (which may be needed in clinical settings of tumor recurrence with change in TRAIL sen sitivity phenotype), rGBMn DR4/5 was engineered to express FmC and cocultured with rGBMn DR4/5 STTK cells, followed by treat ment with and without GCV ( fig. S5 ). Addition of GCV resulted (E) GCV titration of DR4/5 KO cancer lines engineered with or without prodrug-converting suicide system HSV-TK in vitro (n = 3 technical replicates). All in vitro experiments were repeated at least twice. Means ± SD are shown. P values by unpaired t test. **P < 0.01, ***P < 0.001.
in not only cell death in the rGBMn DR4/5 STTK therapeutic line but also elimination of TRAILresistant DR4/5 KO selfcells (rGBMn DR4/5 FmC) via the bystander effect ( fig. S5B) . Thus, should tumors acquire a DR L resistant phenotype during adjuvant clinical therapy and tumor recurrence, the TKinduced bystander effect of therapeutic selfcells might still provide robust treatment efficacy ( fig. S5, A and B) .
CRISPR-engineered tumor cells expressing cytotoxic
The three outlined scenarios feature the potential of selftargeting for (i) local treatment of surgically controllable (primarily nodular) tumor recur rence, (ii) local treatment of recurrent (primarily invasive) cancers for which surgical debulking is not indicated, and (iii) systemic treatment for disseminated/metastatic disease.
(1) Nodular recurrent GBM resection model. On the basis of our previous work with orthotopic GBM resection mouse models, local retention of therapeutic cells can be achieved by encapsulation of therapeutic cells into biodegradable synthetic extracellular matrix (sECM) before implantation into the resection cavity (16) . First, efficacy of sECMencapsulated rGBMn DR4/5 STTK cells against sGBMnRecFmC selfcells was confirmed via in vitro coculture, indicating efficient release of ST out of the sECM (Fig. 5A) . Further more, rGBMn DR4/5 STTK was coengineered to express GFl fol lowed by sECM encapsulation and intracranial implantation into SCID mice to test for in vivo growth and efficiency of GCVinduced (HSVTK-mediated) cell clearance. Implanted sECMencapsulated rGBMn DR4/5 STTKGFl localized to the implantation site and demon strated in vivo growth, and GCV treatment resulted in successful cell clearance, as indicated by a drop of BLI signal back to baseline by day 9 after initiation of GCV therapy (Fig. 5B) . Together, these data show that ST can be released from sECMencapsulated CRISPR engineered therapeutic tumor cells and that these cells retain their potential for in vivo growth but can be eliminated with GCV. On the basis of these observations, we next tested the in vivo antitumor efficacy of sECMencapsulated rGBMn DR4/5 STTK in a clinically relevant resection model of mice bearing recurrent GBM. Mice im planted with the recurrent TMZtreated autologous GBM cell line sGBMnRecFmC (Fig. 4 , A to C) underwent either no treatment (control) or fluorescence microscopy-guided subtotal tumor resection with or without simultaneous implantation of sECMencapsulated rGBMn DR4/5 STTK into the resection cavity followed by treatment with or without GCV (Fig. 5C ). As expected, tumor volume was sig nificantly reduced immediately after GBM resection, as indicated by a drop of the BLI signal after surgery (P < 0.01; Fig. 5C ). Mice undergoing tumor resection and rGBMn DR4/5 STTK implantation demonstrated a marked survival benefit compared to nonresected control mice and mice with resection alone. Survival was further extended in mice receiving GCV treatment (Fig. 5C) .
(2) Invasive recurrent GBM model. To investigate antitumor effi cacy in the clinical setting of nonresectable recurrent tumors, we chose the highly invasive recurrent sGBMiRecFmC model (Fig. 4 , A to C) and used direct stereotactic implantation of rGBMi DR4/5 (control) or therapeutic rGBMi DR4/5 STTK into the tumor site (Fig. 5D) . A marked reduction of tumor burden was observed in rGBMi DR4/5 STTKtreated mice in comparison to control mice (Fig. 5D) . In comparison to controls, therapy with rGBMi DR4/5 STTK and GCV resulted in significant improvements of survival (P < 0.01; Fig. 5D ). Although initially effective in reducing sGBMiRecFmC tumor growth, treatment with rGBMi DR4/5 STTK alone (without GCV) did not significantly improve mouse survival. This is likely a consequence of therapeutic tumor cell growth and underlines the importance of GCV treatment when using therapeutic tumor cells.
(3) Metastatic breasttobrain cancer model. To extend the ap plicability of the aboveoutlined autologous selftargeting approaches to other tumor models, we further investigated their efficacy in a metastatic cancer model using the DR L sensitive breasttobrain meta static cell line sBCm (Fig. 1, C and D) , which was previously established by Bos et al. (23) from the cell line MDAMB231. DR4/5 double KO clone rBCm DR4/5 (sBCmDR4/52; Fig. 3H ) was engineered to express ST and TK; TRAIL expression and secretion were confirmed by Western blotting and ELISA analysis of conditioned medium over time (figs. S3, B and C, and S4). In vivo, mice bearing sBCm tumors engineered to express RlmCherry (sBCmRmC; fig. S3A ) were treated by injecting autologous rBCm DR4/5 STTK cells into the ICA as previously described (24) . In comparison to control mice, mice treated with rBCm DR4/5 STTK and GCV showed marked re duction in tumor growth and prolonged survival (Fig. 5E) .
Analysis of brain sections from mice bearing sGBMnFmC and sGBMiFmC using H&E staining and fluorescence microscopy confirmed close proximity of therapeutic cells and targeted tumor deposits GFP cells starting at 1 week after implantation, with a steady increase of migrating cells over the followup period of 1 month, and cells covering a distance of more than 2 mm in this time period (Fig. 6) . Together, our in vivo data indicate that CRISPRmodified cancer cells engineered to secrete receptortargeted therapeutic mol ecules can specifically target and kill autologous selfcells in mouse models of recurrent and metastatic cancers and that treatment in creases the survival of mice.
DISCUSSION
This study demonstrates the therapeutic potential of using engi neered tumor cells and their selfhoming properties for developing receptortargeted therapeutics for various cancers. We show the feasibility and clinical translatability of this approach by using (i) offtheshelf tumor cells resistant to DR L , which could be used for targeting of allogeneic patient tumors in clinical scenarios of primary tumor treatments, and (ii) inherently DR L sensitive tumor cells, which, after CRISPRmediated DRKO, can be used in autologous unpaired t test (C, top) or Mantel-Cox (log-rank) test (survival curves), *P < 0.05, **P < 0.01, ****P < 0.0001.
settings of recurrent or metastatic disease. Moreover, this study highlights the advantages of combining tumor cell-based receptor targeting with prodrugactivatable suicide systems and, using optical and PET imaging, demonstrates the feasibility, therapeutic efficacy, and safety of this approach in clinically relevant mouse models of primary, recurrent, and metastatic disease.
Despite great leaps in the treatment of malignant neoplasms over the past decades, cancer remains the second most common cause of death in the western world, slightly surpassed only by heart disease, and currently accounts for nearly one of every four deaths in the United States (25, 26) . Consequently, new therapeutic approaches are desperately needed, especially in cases of recurrent and meta static disease, where standard therapy has failed and evidencebased options for salvage treatments are limited or lacking. Preclinical data increasingly indicate that cellbased therapies enabling local delivery of therapeutic agents might provide a valuable option for these cases, and multiple studies are currently ongoing with the goal of translating these approaches into clinical settings (27) (28) (29) (30) . Associated advantages are man ifold and include achievement of con tinuously high local concentrations of secreted agents with reduction of sys temic toxicity, delivery of molecules with short halflives that are inefficacious when used systemically, exposure or aid in de tection of tumorspecific antigens, and consecutive activation of the immune system, as well as the application of the pathotropic abilities of therapeutic cells to track tumor microdeposits.
Traditionally, the main focus of re search in the field of cellbased therapies has been on stem cells (SCs). In addition to the possibility of modifying these cells to express various proapoptotic and an tiproliferative molecules, SCs' inherent pathotropic properties and their intrin sic antitumor effects have rendered them promising tools in the treatment of mul tiple cancers (29, 31) . In the setting of GBM in particular, SC transplantation may enable local delivery of molecules that cannot cross the bloodbrain barrier when administered systemically. How ever, despite the apparent advantages of using SCs for certain cancer types, sev eral inherent and external roadblocks are still restricting widespread clinical trans lation of SCbased therapies: (i) Adult SCs are often slowgrowing in vitro and, unless artificially immortalized, (ii) have a limited passage number, which makes engineering them with therapeutic mole cules difficult and reduces treatment ef ficacy because of short in vivo survival (32); (iii) donor SCs, prepared from a healthy individual or from a pool of healthy donors, may not (or only partial ly) match the recipient's HLA status, possibly causing adverse immune responses and/or toxicity, as well as premature SC clearance by the recipient's immune system (33); and (iv) autologous SC transplantation would be ideal but is time consuming and, therefore, currently not practical in firstline treat ment or for patients with endstage cancer because SCs have to be harvested, reengineered with therapeutic molecules, and expanded before reapplication can be considered (34) . Moreover, SC harvesting from patients necessitates further interventional procedures, therefore adding to the overall risk of clinical complications, especially for late stage and immunocompromised patients after chemotherapy.
Numerous studies have investigated the mechanisms that influence tumor progression and eventually contribute to metastasis (2, 3) . One concept suggests that, during tumor evolution, cancer cells gain the ability of "selfseeding," a process involving cell dissemination into the vascular system away from the primary or metastatic tumor, fol lowed by the cells rehoming to the site of origin (4, 35, 36) . The ex act factors involved in this mechanism are still poorly understood, but studies suggest that, besides leaky primary tumor vasculature with impaired barrier function, cytokinereceptor interactions be tween the primary tumor and circulating cancer cells may play a major role (36) (37) (38) . On the basis of these findings, several studies have investigated approaches to repurpose the selfhoming properties of tumor cells for selftargeted delivery of anticancer agents to pri mary tumor sites (5) (6) (7) (8) (9) . Exploring the clinical scenario associated with this approach, cancer cells harvested at the time of tumor surgery would be introduced to culture conditions and engineered with an ticancer agents, followed by local or systemic reapplication of autol ogous therapeutic cells upon tumor recurrence. Possible advantages, in comparison to the abovementioned SCbased therapies, are en hanced homing of therapeutic cancer cells toward the primary tumor site, ease of engineering with therapeutic molecules due to robust growth in vitro, prolonged therapeutic cell survival resulting in en hanced therapeutic efficacy in vivo, and their ready availability for autologous therapy because tumor biopsy is part of standard man agement for the vast majority of cancer patients. In comparison to allogeneic approaches, treatment with autologous cells additionally does not increase the risk of adverse immune response and/or toxicity, as well as premature therapeutic cell clearance by the recipient's immune system.
Previous studies exploring selftargeted cancer therapies, to our best knowledge, have focused on three different approaches: (i) the use of cancer cells as a vehicle for delivery of oncolytic viruses (5, 6) , (ii) the use of bystander effect by engineering tumor cells with suicide genes (7, 8) , and (iii) engineering tumor cells to secrete TNF, a cytokine known for its ability to induce hemorrhagic necrosis in solid tumors due to its damaging effect on tumors' neovascular endothelium (9, 39) . Although approaches (i) and (ii) incorporate therapeutic tumor cell elimination, a safety feature indispensable for possible future clinical translation, anticancer efficacy of these approaches might be limited because of spatiotemporal limitations if therapeutic cells are eliminated or die before reaching the primary or metastatic tumor sites. In addition, bystander effect due to suicide gene ex pression is only a onetime effect, which subsides once therapeutic cells are eliminated. TNF-secreting tumor cells (3) have shown promising preclinical results (9) . However, TNF is a rather un specific anticancer agent because its primary target receptor, TNF receptor 1, is ubiquitously expressed and mediates a large variety of effects (40) , including inflammation and tissue degeneration, which may be associated with unwanted side effects (41) .
Our study explored combining the advantages of suicide systeminduced therapeutic cancer cell elimination with the continuous ex pression of a receptortargeted anticancer agent. The DRtargeted apoptosisinducing ligand, TRAIL, was specifically chosen for its superior anticancer efficacy when tested against other receptortargeted molecules in a panel of tumor cell lines including solid and nonsolid, as well as primary, recurrent, and metastatic lines. Besides TRAIL's receptortargeted properties and its ability to strongly induce apo pto sis in a wide range of human cancer cell lines, it has the advantage of not inducing cytotoxicity in normal cells and can be engineered in a secretable form (ST) (42) (43) (44) . However, although these properties seem ideal for selftargeted therapy, TRAILsensitive cancer cells cannot readily be engineered with ST because of autocrine toxicity. We therefore explored different selftargeting approaches to avoid TRAILinduced selftoxicity, each aimed at specific, clinically relevant cancer treatment scenarios. In models of primary cancer treatment, we show that TRAILresistant cancer cells can be readily engineered with ST and used offtheshelf for targeting TRAILsensitive GBM. However, ideally, one would like to use autologous cells for self targeting, thereby avoiding possible immunemediated premature elimination of therapeutic cells and adverse effects. Our studies in dicate that such an autologous approach can be realized by using CRISPR technology to knock out TRAIL receptors DR4 and DR5, thereby reversing the TRAILsensitivity phenotype and allowing en gineering of previously TRAILsensitive cancer cells with ST.
Considering the time needed for engineering of autologous cell lines, treatment with KO lines should be aimed at therapy of recurrent or systemic/metastatic disease. Consequently, we used autologous KO lines either in mouse models of tumor recurrence or in a meta static breasttobrain model using the cell line sBCm, which was established through several rounds of brain selection of breast car cinoma cells (23) . Besides reflecting different cancer models (primary, recurrent, and metastatic), cell lines used in this study were further selected on the basis of their in vivo growth characteristics. sBCm was specifically chosen to investigate selftargeting in metastatic settings based on a previous report (36) , which demonstrated sBCm's highly efficient selftargeting phenotype in mouse models of primary breast cancer and lung metastasis (using lung metastatic derivative MDA231LM2). The TRAILsensitive recurrent cell lines sGBMiRec FmC (invasive growth) and sGBMnRecFmC (nodular growth), on the other hand, reflect the different in vivo phenotypes of recurrent GBM to mimic the clinical scenarios where a second (recurrent) tumor resection is possible (nodular), versus the case of a nonresectable recurrent GBM (invasive model). On the basis of these in vivo growth characteristics, we further adapted techniques for in vivo therapy. In the nodular recurrent model (sGBMnRecFmC), we aimed to retain therapeutic cancer cells within close proximity to remaining tumor tissue by encapsulating therapeutic cells into syn thetic biodegradable ECM before implantation into the resection cavity. In models of highly invasive recurrent GBM, however, resec tion is not an option, which is why direct implantation of non encapsulated therapeutic cancer cells was used instead. Moreover, to promote homing to invasive tumor deposits, therapeutic cells were not ECMencapsulated whenever direct implantation into in vasive tumors was used. Our migration studies indicated that non encapsulated CRISPRengineered cells retain their ability for targeted delivery of therapeutics toward selftumor sites. Although the ex act mechanisms underlying the selftargeting of tumor cells remain to be further elucidated, studies have suggested multiple theories to explain this phenomenon. In addition to common cytokinereceptor interactions that mediate directed cell migration, the establishment of a favorable tumor microenvironment, which supports survival of migrating tumor cells, may play a crucial role in this process (36, 45, 46) . In addition, it has been demonstrated that IL6 and IL8 might serve as tumorderived attractants, and fascin actinbundling protein 1 and matrix metalloproteinase 1 might additionally be involved in mediating migration (23, 36, (47) (48) (49) (50) .
In metastatic disease, resection is also often not possible because of metastatic tumor location and/or the large number of metastatic deposits. To mirror this scenario, breasttobrain metastatic cell line sBCm was implanted intracranially into mice, followed by applica tion of therapeutic cells via ICA injection, thereby reflecting systemic treatment of metastatic disease. Using the aboveoutlined models, our studies demonstrated that CRISPRmodified therapeutic cancer cells can directly kill selfcells via TRAILinduced apoptosis in vitro and in vivo and that, in combination with their selfhoming properties, these effects increase the survival of mice bearing autologous recur rent or metastatic tumor deposits. Although it is known that sBCm exhibits a highly efficient selftargeting phenotype (36) , future studies will have to explore whether systemic treatment scenarios are also feasible for metastatic models of other cancer types.
One of the main concerns for treatments using therapeutic cancer cells is their tumorigenic potential. Here, we incorporated a prodrug activatable suicide system to address this concern. Our in vivo data demonstrate that therapeutic cancer cells expressing HSVTK can be safely eliminated, and we did not observe recurrences of thera peutic cells after in vivo GCV treatment. This is in line with clinical studies, which demonstrated a robust safety profile of HSVTK systems when used on proliferating cells in patients (51, 52) . The importance of GCVinduced therapeutic cancer cell elimination is highlighted by our in vivo survival studies, which showed that selftargeted therapy without GCV treatment did not provide overall survival benefit in nonresected tumor models. This is likely the case because therapeutic tumor cells retain their potential for in vivo growth and, even if very efficacious in treating the selftumor site (as shown by the drop in BLI signal), will therefore eventually outgrow the targeted tumor cells and result in premature animal death if no GCV treatment is ad ministered. Therefore, if these are considered for clinical translation, therapeutic cancer cells should be confirmed to have stable HSVTK expression, and GCV will need to be administered to all patients. Moreover, adding a second suicide system (53-55) should be con sidered, and largerscale preclinical studies focused on analyzing the safety profile of this approach should be performed. In case of clinical translation, an advantage of the HSVTK system is that it can be used to noninvasively monitor the fate of therapeutic cells via PET imaging in combination with radioactive substrates, such as the 18F FHBG used in this study (56, 57) .
Besides ensuring safety, our in vitro data demonstrate that HSV TK-induced cell elimination is associated with a bystander effect, which may contribute to the overall treatment efficacy in cases of secondary TRAIL resistance. In clinical settings, HSVTK-mediated tumor cell elimination might further boost therapeutic efficacy via exposure of tumor antigens followed by tumorspecific immuno activation, which may be especially helpful in cases of tumors with heterogeneous DR L sensitivity (58) (59) (60) .
Here, engineering and generation of therapeutic cell lines required transduction with multiple vectors and clonal selection, which was timeconsuming and laborintensive. Further studies are necessary to make this process more efficient and increase clinical feasibility. Lessons learned from the recent introduction of chimeric antigen receptor (CAR) T cells into clinical practice and current efforts to increase CARs' efficacy via multistep engineering may provide valu able expertise during this process. Another challenge during clinical transla tion may be immune reactions to engineering vectors or the expressed transgenes, especially Cas9 (61, 62) . Although implemen tation of an inducible Cas9 system, as used in this study, will limit Cas9 expression after KOs are achieved, nonconstitutive expression strategies would be preferred.
Moreover, although DR L based therapies have demonstrated great efficacy in many preclinical studies, efforts for their clinical transla tion have so far been disappointing. We believe that the two main reasons for the failure of previous clinical studies using TRAIL therapy are likely (i) inefficient patient stratification as a result of missing screening of patients for their tumors' TRAIL sensitivity phenotype and (ii) reduced efficacy of TRAIL treatment due to spatiotemporal (short halflife, rapid clearance) and dose toxicity issues when TRAIL was administered systemically (63) (64) (65) . This study demonstrates that (ii) might be solved by local delivery of TRAIL via transplantation of therapeutic cells directly into the vicinity of the targeted tumor site. Because of the continued secretion of TRAIL at the tumor site (in contrast to intermittent systemic treatment), this approach not only overcomes toxicity problems reported for systemic treatment but also addresses issues of inadequate local TRAIL concentration. Here, we additionally addressed the issue of inefficient patient se lection (i) by screening tumor cell lines for TRAIL sensitivity. This approach reflects a clinical scenario where patients' tumor cells are screened for TRAIL sensitivity before treatment initiation. To trans late this screening process into future patient therapy, one could try to isolate patients' circulating cancer cells upon admission and screen them for DR expression when an allogeneic offtheshelf approach is favored (66) . Another option is to isolate and culture patients' own tumor cells after the first surgery and test them for TRAIL sensitivity in vitro before CRISPR modification and engineering with ST. Each patient's own therapeutic cells could then be readministered once the patient is readmitted for recurrent surgery (autologous approach), assuming that the recurrent tumor will retain its TRAILsensitive phenotype (as our data suggest).
Recent studies on the TRAILinducing smallmolecule ONC201/ TIC10 have shown promising results in a variety of cancers (67) (68) (69) . ONC201 induces apoptosis in a p53independent manner via selective antagonism of D2like dopamine receptors (DRD2) and ultimately results in TRAIL induction. ONC201 is orally active and crosses the bloodbrain barrier, thus making it a promising agent for future therapy of GBMs (68) . However, because ONC201 (unlike TRAIL) does not directly act on DRs, its clinical efficacy not only may depend on DRD2 and DR expression in tumor cells but also further relies on preserva tion of (downstream) pathways for Akt, ERK, and TRAIL. This might potentially reduce the number of targetable tumors and may further increase the potential for resistance. Therefore, local cellbased secretion of TRAIL as suggested in this study may provide higher efficacy.
In conclusion, our studies reveal the fate, therapeutic efficacy, and safety of engineered receptortargeted human tumor cells in xeno graft mouse models of primary, recurrent, and metastatic cancer. This study supports clinical development of cancer therapy that uses ge netically engineered allogeneic or autologous tumor cells in cancer patients. We envision that, after the removal of the main tumor mass, patients' own cancer cells will be ex vivo engineered with receptor targeted antitumor agent(s), as well as an inducible suicide system before they are readministered via different routes, depending on the type and clinical stage of cancer. These cells would result in killing of residual, invasive, and metastatic tumor deposits with the ultimate goal of improving outcomes.
MATERIALS AND METHODS
Study design
This study was designed to evaluate the fate, therapeutic efficacy, and safety of receptortargeted ligandsecreting human tumor cells. This objective was addressed by (i) determining suitable receptor targeted ligands, (ii) evaluating the selftargeting efficacy of inher ently ligandresistant tumor cells for therapeutic use against inherently sensitive cancer cell lines of the same cancer type, (iii) assessing the feasibility of CRISPRmediated KO of ligand receptors to switch cancer cells' ligandsensitivity phenotype from sensitive to resistant before engineering with previously selftoxic ligand, and (iv) assessing the in vitro and in vivo selftargeting efficacy of these ligandsecreting therapeutic tumor cells.
In animal studies, mice were randomized to groups according to tumor volume at the start of treatment. The number of mice per group varied between experiments and is specified in the figure leg ends. The primary end point was survival. All in vivo procedures were approved by the Subcommittee on Research Animal Care at Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH). All in vitro and in vivo results are representative of two to five independent experiments. The investigators were not blinded during the study.
Statistical analysis
Data were expressed as means ± SD for in vitro studies and means ± SEM for in vivo studies and analyzed by Student's t test when com paring two groups. Survival times of mouse groups were analyzed and compared using logrank test. GraphPad Prism 5 Software was used for all statistical analysis and also to generate KaplanMeier survival plots. Differences were considered significant at *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
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